In the trial of 45 volunteers, conducted by the National Institute of Allergy and Infectious Diseases, eight volunteers who got two doses of the vaccine produced protective antibodies roughly on par with people who recovered from a natural infection of the virus that causes the COVID-19 illness, the U.S. biotechnology company said in a news release.

Advertisement

Here is some more scientific information about the phase I trials, and the upcoming phase II trials.

Advertisement

Share This Story

Get our newsletter